Skip to content

Effectiveness of T2* MRI in Cervical Spondylotic Myelopathy

Effectiveness of T2* MRI in Predicting Prognosis in Patients With Cervical Spondylotic Myelopathy (CSM)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04955041
Enrollment
200
Registered
2021-07-08
Start date
2010-01-31
Completion date
2022-06-30
Last updated
2021-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Spondylotic Myelopathy

Brief summary

Utilization of T2\* MRI in predicting prognosis in patients with cervical spondylotic myelopathy (CSM)

Detailed description

Cervical spondylotic myelopathy (CSM), an age-related degenerative disease that is common worldwide, is mainly caused by compression of the spinal cord and may possibly lead to disability. Surgery to reduce direct compression of the spinal cord might alleviate disease progression; due to individual differences, some patients do not benefit from surgery. Prognostic prediction is important because it affects subsequent treatment decision making. Currently, prognosis is generally based on magnetic resonance imaging (MRI) with a detailed macrostructural evaluation of the spinal cord. Unfortunately, the use of conventional MRI indicators (e.g., increased intensity signal \[ISI\]) to predict CSM outcomes has been controversial because of their subjectivity or the insufficient information contained therein. A new biomarker, T2\* MRI gray matter to white matter signal intensity ratio (GM/WM), is associated with demyelination and gliosis. Previous studies have shown that patients with CSM can have T2\* MRI WM / GM changes at the early stage of disease, and the WM / GM value is increased, which is significantly higher than that of normal people, and is related to the spinal cord function score. However, the correlation between this index and long-term prognosis remains to be studied.

Interventions

OTHERMRI

T2\* MRI

Sponsors

Peking University Third Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* diagnosed with CSM and operated on by one senior orthopedist * available preoperative MRI results * high-quality image data with no motion artifacts * available preoperative and long-term follow-up (≥1 years) mJOA score

Exclusion criteria

* prior head or neck surgery * a history of notable additional diseases (spinal cord tumor, multiple sclerosis, syringomyelia, spinal cord injury, or motor neuron disease).

Design outcomes

Primary

MeasureTime frameDescription
Improvement of neurologic functionat follow-up time (≥1 years)Postoperative modified Japanese Orthopaedic Association (mJOA) at follow-up time

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026